TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.
Toni K. Choueiri(Harvard University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Rana R. McKay(University of California San Diego), Laurence Albigès(Université Paris-Saclay), Hans J. Hammers(Southwestern Medical Center), Daniel Yick Chin Heng(University of Calgary), Vijay Kasturi(AVEO Oncology (United States)), Katy Beckermann(Vanderbilt University Medical Center), Sumanta K. Pal(City of Hope)
Cited by 3
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k